Bayer vs. Novartis eye-drug fight intensifies; Pfizer's thyroid med faces sales hurdles; AZ media chief jumps ship;

> Britain's cost-effectiveness gatekeepers backed a new use for Bayer's Eylea vision treatment, in patients with macular edema, stepping up its rivalry with Novartis' ($NVS) Lucentis drug. Report

> Pfizer ($PFE) will resume shipping its thyroid drug Levoxyl after a manufacturing snafu caused a long hiatus; the company now faces a challenge in regaining market share from AbbVie's ($ABBV) Synthroid and generic drugs. Report

> AstraZeneca's ($AZN) global head of media relations, Neil McCrae, has jumped ship to join Royal Mail as its deputy director of communications. Report

> KV Pharmaceutical ($KV.A) created a new maternal health division to focus on marketing products for pregnancy management and tapped Alere Health's Gregg Raybuck to be president of the unit. Report

> Forest Laboratories ($FRX) launched a new support program for chronic obstructive pulmonary disease patients using its treatments for the disease, Tudorza Pressair and Daliresp. Release

> India's Dr Reddy's Laboratories saw its stock surge today after it launched its injectable version of Imitrex, GlaxoSmithKline's ($GSK) migraine drug, in the U.S. Report

And Finally... Algeta shareholders have now tendered more than 97% of their shares to Bayer in the German drugmaker's 2 billion euro takeover. Report

Suggested Articles

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.